R. Schnell

614 total citations
28 papers, 469 citations indexed

About

R. Schnell is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, R. Schnell has authored 28 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 14 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Oncology. Recurrent topics in R. Schnell's work include Monoclonal and Polyclonal Antibodies Research (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Toxin Mechanisms and Immunotoxins (9 papers). R. Schnell is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Toxin Mechanisms and Immunotoxins (9 papers). R. Schnell collaborates with scholars based in Germany, United States and Austria. R. Schnell's co-authors include Andreas Engert, Peter Borchmann, Volker Diehl, John Schindler, Victor Gheţie, Stefan Barth, Jan Oliver Staak, E S Vitetta, E S Vitetta and Peter Staib and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

R. Schnell

26 papers receiving 458 citations

Peers

R. Schnell

IMMUN

ONCOL

PFM

BIOTE

RNMI

R Nadeau United States

Joan A. Stratton United States

Masanori Sakurai United States

Carlos Eduardo Coral de Oliveira Brazil

Amy Sun United States

Chunxiao Liu China

Sei Kyung Chang South Korea

Maria Dan United States

John Anderson United Kingdom

B B Lozzio United States

R Nadeau United States

R. Schnell

271 ×1.3

IMMUN

179 ×1.2

ONCOL

27 ×0.2

PFM

37 ×0.3

BIOTE

50 ×0.5

RNMI

Citations per year, relative to R. Schnell R. Schnell (= 1×) peers R Nadeau

Countries citing papers authored by R. Schnell

Since Specialization

Citations

This map shows the geographic impact of R. Schnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Schnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Schnell more than expected).

Fields of papers citing papers by R. Schnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Schnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Schnell. The network helps show where R. Schnell may publish in the future.

Co-authorship network of co-authors of R. Schnell

This figure shows the co-authorship network connecting the top 25 collaborators of R. Schnell. A scholar is included among the top collaborators of R. Schnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Schnell. R. Schnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schnell, R., Jessica L. Mitchell, Joleen M. Hubbard, et al.. (2023). Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis. Cancers. 15(14). 3570–3570. 1 indexed citations

Dietlein, Markus, Thomas Fischer, Hinrich P. Hansen, et al.. (2010). Entwicklung von Anti-CD30-Radioimmunkonstrukten zur Behandlung des Hodgkin-Lymphoms – Studien an Zellkulturen und Tieren. Nuklearmedizin - NuclearMedicine. 49(3). 97–105. 6 indexed citations

Fischer, Thomas, Hinrich P. Hansen, R. Schnell, et al.. (2010). Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Nuklearmedizin - NuclearMedicine. 49(3). 97–105. 8 indexed citations

Borchmann, Peter, Karolin Behringer, Andreas Josting, et al.. (2005). Sekundärneoplasien nach erfolgreicher Primärtherapie des malignen Hodgkin-Lymphoms. Der Pathologe. 27(1). 47–52. 2 indexed citations

Borchmann, Peter, R. Schnell, & Andreas Engert. (2005). Immunotherapy of Hodgkin's lymphoma. European Journal Of Haematology. 75(s66). 159–165. 6 indexed citations

Heller, G, et al.. (2003). Warum ist die Sterblichkeit von nachts geborenen Kindern erhöht?. Zeitschrift für Geburtshilfe und Neonatologie. 207(4). 137–142. 9 indexed citations

Dietlein, Markus, Andreas Engert, Martin R. Weihrauch, et al.. (2003). Hodgkin’s lymphoma in nuclear medicine: diagnostic and therapeutic aspects. Nuklearmedizin - NuclearMedicine. 42(1). 19–24. 3 indexed citations

Schnell, R., et al.. (2003). Hat die Größe der Geburtsklinik Einfluss auf das neonatale Überleben?. DMW - Deutsche Medizinische Wochenschrift. 128(13). 657–662. 6 indexed citations

Schnell, R.. (2002). Non-myeloablative radioimmunotherapy with a Iodine-131-tagged anti-CD30 antibody (^ I-Ki-4) in patients with refractory Hodgkin Lymphoma. Blood. 100(1). 2 indexed citations

10.

Schnell, R., Peter Borchmann, H. Schulz, & Andreas Engert. (2002). Current strategies of antibody‐based treatment in Hodgkin's disease. Annals of Oncology. 13. 57–66. 22 indexed citations

11.

Borchmann, Peter, R. Schnell, Jan Oliver Staak, et al.. (2001). Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma. Annals of Oncology. 12(5). 661–667. 44 indexed citations

12.

Schnell, R., W. Hiddemann, Volker Diehl, & Andreas Engert. (2001). Klinischer Einsatz monoklonaler Antikörper bei malignen Lymphomen. Der Internist. 42(6). 815–826. 1 indexed citations

13.

Schnell, R., E S Vitetta, John Schindler, et al.. (2000). Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia. 14(1). 129–135. 56 indexed citations

14.

Hübel, Kai, R. Schnell, G. Mansmann, et al.. (1999). Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Annals of Hematology. 78(2). 73–77. 44 indexed citations

15.

Schnell, R., E S Vitetta, John Schindler, et al.. (1998). Clinical Trials with an Anti-CD25 Ricin A-Chain Experimental and Immunotoxin (RFT5-SMPT-dgA) in Hodgkin's Lymphoma. Leukemia & lymphoma. 30(5-6). 525–538. 47 indexed citations

16.

Reiser, Marcel, R. Schnell, Peter Borchmann, et al.. (1998). DIZE (Dexamethasone, Idarubicin, and Continuous Infusion of Ifosfamide and Etoposide): an Effective and Well-Tolerated New Regimen for Patients with Relapsed Lymphoma. Leukemia & lymphoma. 31(3-4). 359–366. 12 indexed citations

17.

Borchmann, Peter, R. Schnell, Volker Diehl, & Andreas Engert. (1998). New drugs in the treatment of Hodgkin’s disease. Annals of Oncology. 9. s103–s108. 25 indexed citations

18.

Engert, Andreas, R. Schnell, Marcel Reiser, et al.. (1997). A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma. Leukemia & lymphoma. 24(5-6). 513–522. 13 indexed citations

19.

Barth, Stefan, et al.. (1996). Development of immunotoxins for potential clinical use in Hodgkin's disease. Annals of Oncology. 7. S135–S141. 13 indexed citations

20.

Schnell, R., Gisela Schön, Heribert Bohlen, et al.. (1995). 930 A clinical phase I study of an anti-CD25-deglycosylated ricin A-chain immunotoxin (RFT5-SMPT-DGA) in patients with refractory Hodgkin's disease. European Journal of Cancer. 31. S193–S193. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact